Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 23Breast Neoplasms 12Prostatic Neoplasms 11Triple Negative Breast Neoplasms 7Fallopian Tube Neoplasms 7Stomach Neoplasms 5Neoplasm Metastasis 5Sarcoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Metastatic Castration-resistant Prostate Cancer 4Fanconi Anemia, Complementation Group D1 4Small Cell Lung Carcinoma 3Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Wilms Tumor 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Pancreatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Endometrial Neoplasms 2

Interventions

Paclitaxel 22Carboplatin 18liposomal doxorubicin 14Bevacizumab 9Topotecan 8Docetaxel 8Gemcitabine 7Cisplatin 7rucaparib 6pembrolizumab 6mirvetuximab soravtansine 5Cyclophosphamide 5Taxes 4Albumin-Bound Paclitaxel 4sargramostim 3ixabepilone 3Cytoreduction Surgical Procedures 3CCV-AV protocol 3130-nm albumin-bound paclitaxel 3taxane 2talazoparib 2pazopanib 2olaparib 2fludarabine phosphate 2fludarabine 2denileukin diftitox 2cediranib 2catumaxomab 2belinostat 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Carcinoma, Ovarian Epithelial × olaparib × Clear all
NCT04377087 2024-08-20

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

University of Pittsburgh

Phase 2 Terminated
3 enrolled 9 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT03106987 2022-10-07

OReO

AstraZeneca

Phase 3 Completed
220 enrolled 21 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡